Missense mutations in the CITED2 gene may contribute to congenital heart disease

• Published in: BMC cardiovascular disorders 2024-09, Vol.24 (1), p.516-10, Article 516
• Main Authors: Yaqoob, Hira, Ahmad, Hussain, Ali, Syed Irtiza, Patel, Najma, Arif, Afsheen
• Format: Article
• Language: English
• Subjects: Adolescent; Allele-specific PCR; Analysis; Cardiovascular disease; Care and treatment; Case-Control Studies; Chi-square test; Child; Child, Preschool; China - epidemiology; CITED2 gene; Congenital diseases; Congenital heart disease; Congenital heart disease (CHD); Defects; DNA Mutational Analysis; DNA sequencing; Female; Gene Frequency; Gene mutations; Gene polymorphism; Genes; Genetic analysis; Genetic aspects; Genetic Association Studies; Genetic engineering; Genetic Predisposition to Disease; Genetic testing; Genotype; Genotype & phenotype; Health aspects; Heart; Heart Defects, Congenital - diagnosis; Heart Defects, Congenital - genetics; Heart diseases; Heterozygote; Homozygote; Humans; Hypoxia; Infant; Male; Missense mutation; Mutants; Mutation; Mutation, Missense; Nucleotide sequencing; Phenotype; Point mutation; Polymorphism, Single Nucleotide; Proteins; Repressor Proteins - genetics; Risk Factors; Sequencing; Single nucleotide polymorphism (SNP); Single nucleotide polymorphisms; Single-nucleotide polymorphism; Tetralogy of Fallot; Trans-Activators - genetics
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-024-04035-2

Congenital heart disease (CHD) is a lifelong abnormality present from birth. Multiple studies have shown that mutations in genes involved in heart development could cause congenital heart disease. The CITED2 gene works as a transcription factor in the hypoxic pathway for the development of the heart. Therefore, five CHD types, ventricular septal defect, atrial septal defect, atrioventricular septal defect, tetralogy of fallot, and patent ductus arteriosus, were evaluated by conducting a targeted single nucleotide polymorphism (SNP) analysis of the CITED2 gene variant rs375393125 (T > C). This study aimed to identify the association of CITED2 gene mutations in CHD patients. Three hundred fifty samples, 250 from patients and 100 from controls, were collected for this genetic analysis. Allele-specific PCR and gel electrophoresis were used to identify the target missense mutations. The genotypic results of the CHDs were further validated through Sanger sequencing. The frequency of the homozygous mutant (CC) in CHD patients was 48.4%, and of the heterozygous mutant (TC) genotype was 11.4%; these percentages are higher than controls (1%). The control samples had only one heterozygous TC and no homozygous CC genotype. The chi-square value was obtained at 103.9 with a probability of 0.05, more significant than the significance value of 21.03. The odds ratio was 43.7, which is > 1. The calculated value of ANOVA was 11.6, which was more significant than the F critical value of 3.7. As a result of sequencing, the mutant sample of each selected CHD type was found heterozygous or homozygous, and the results were like those obtained through conventional PCR. The samples of CHD patients showed mutations. Therefore, the CITED2 gene SNP might be associated with CHD.